Anthrax Vaccine rPA mrPA Adjuvant Reactogenicity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current anthrax vaccines, such as BioThrax, exhibit significant reactogenicity and require multiple boosters to maintain protective immunity, limiting their effectiveness and safety for widespread use.

Innovation Solution

An immunogenic composition comprising 5 mcg-100 mcg of B. anthracis recombinant protective antigen (rPA) or mutant rPA (mrPA) protein combined with liposome-embedded MPLA adjuvant, or mrPA protein without adjuvant, is developed to induce an immune response against anthrax.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If BioThrax vaccine is used for anthrax prevention, then protective immunity is achieved, but significant reactogenicity occurs

Engineering Contradiction:

Improveprotective immunityVSAvoidreactogenicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts only the essential protective antigen component (rPA or mrPA protein) from the crude culture supernatant used in BioThrax, eliminating other bacterial components that cause reactogenicity. This purification approach maintains immunogenicity while reducing harmful side effects.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent uses mutant rPA (mrPA) with modified amino acid sequences that reduce reactogenicity while preserving protective immunogenicity. Specific parameter changes in the protein structure (mutations) allow differentiation between harmful and beneficial immune responses.

Inventive Principle:

Principle #35Parameter changes

2Duration of action of stationary object

If multiple boosters are administered to maintain protective immunity, then immunity duration is extended, but vaccine complexity and administration burden increase

Engineering Contradiction:

Improveimmunity durationVSAvoidvaccine regimen complexity

Core Design Contradiction:

Duration of action of stationary objectVSDevice complexity

Solution Approach 1:

The vaccine formulation is designed to elicit a strong initial immune response that provides long-lasting protection, reducing the need for multiple booster shots. The adjuvant system and antigen selection are optimized upfront to maximize immunogenicity and duration of protection from fewer doses.

Inventive Principle:

Principle #10Preliminary action

3Object-affected harmful factors

If reformulated vaccine AV7909 is used to reduce reactogenicity, then safety is improved, but multiple boosters are still required to maintain protective immunity

Engineering Contradiction:

ImprovereactogenicityVSAvoidprotective immunity maintenance

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent combines recombinant or mutant protective antigen with specific adjuvants (such as liposome-embedded MPLA) to create a composite vaccine formulation. This composite approach enhances immunogenicity and duration of protection while maintaining reduced reactogenicity, achieving both safety and efficacy goals simultaneously.

Inventive Principle:

Principle #40Composite materials

Data Source

PatentUS20250186570A1Anthrax vaccine

Publication Date: 2025.06.12 PELICAN TECHNOLOGY HOLDINGS INC

AI summary

Provided herein is an immunogenic composition, comprising: 5 mcg to 100 mcg B. anthracis rPA (recombinant protective antigen) or mrPA (mutant rPA) protein and liposome-embedded MPLA (monophosphoryl lipid A) adjuvant. An immunogenic composition comprising 60 mcg to 600 mcg B. anthracis mrPA (mutant rPA) protein, wherein the composition is free of adjuvant, i.e., with no added adjuvant, is also provided. Also described is a method for inducing an immune response to B. anthracis, the method comprising administering the immunogenic composition to the subject.